long-term follow-up of CALGB 10403 in AYA patients with ALL now out in @bloodjournals.hematology.org! pubmed.ncbi.nlm.nih.gov/42101912/

more data in the MPN-AP/BP space - this time from a UK cohort! onlinelibrary.wiley.com/doi/10.1111/...

recent @bloodjournals.hematology.org publication on bomedemstat in myelofibrosis! Modest spleen effect but seemed to have some VAF impact! ashpublications.org/bloodadvance...

A beautiful day for @uchicagocancer.bsky.social heme-onc senior fellows to present their ongoing work!

a very useful article comparing outcomes in del5q with multi-hit TP53m to MDS with low blasts and multi-hit TP53m! www.nature.com/articles/s41...

More data to show how far we need to go to improve outcomes for patients with blast-phase MPNs - virtually no improvement even in the era of venetoclax acsjournals.onlinelibrary.wiley.com/doi/10.1002/...

Perfect day for a post-clinic walk through the UChicago campus

I am looking forward to being a part of this Patient Empowerment Network webinar focused on AML! powerfulpatients.org/event/insist...

Loved being a part of this clinical reasoning exercise as the hematology discussant! urldefense.com/v3/__https:/...

really enjoyed reading this up-to-date review on MPN-AP/BP by Bewersdorf et al! www.sciencedirect.com/science/arti...

Excited to give a talk this weekend to the Mumbai Hematology Group on the less common Ph- MPNs! perfectsquare.co.in/mhgwebinar/s...

fascinating report of a patient with KMT2Ar AML who was treated with revumenib, developed a MEN1 mutation, and then responded to bleximenib! www.nature.com/articles/s41...

Some pics of Chicago over the last few months!

analysis of the QuANTUM-First (chemo + Quiz vs chemo + placebo in FLT3-ITD m AML) study looking at quizartinib maintenance in patients that did not receive allo-HCT -3y OS in pts that achieved FLT3 MRD-negativity without allo-HCT in the quiz maintenance arm! ashpublications.org/bloodadvance...

Really enjoyed speaking about treatment strategies in older adults with ALL at the @onclive.bsky.social State of the Science Summit!

excited to be a part of this effort looking at the impact of CMR on survival outcomes in Ph+ ALL led by @talhabadarmd.bsky.social! www.tandfonline.com/doi/full/10....

really enjoyed talking about R/R NPM1m AML with Dr Arana Yi as part of this @onclive.bsky.social series! www.onclive.com/insights/tre...

an absolute powerhouse effort to develop a comprehensive prognostic score in CMML ascopubs.org/doi/10.1200/...

very interesting article on HLH in AML ashpublications.org/bloodneoplas...

How should we incorporate molecular data in treatment decisions for ALL? It is time to pay more attention to genetic heterogeneity of adult ALL before we decide therapy. Targeted therapies are rapidly emerging, and replacing chemo in ALL. Our review at Blood Cancer Discovery is out today! Link👇

proud to be a part of this effort to give patients more information about myelofibrosis in collaboration with @mpnrf.bsky.social! www.youandmpn.com/en-mpn/view/...

Starting 2 weeks on the leukemia service! Will be sharing daily articles Day 1 - review on blast-phase MPNs pubmed.ncbi.nlm.nih.gov/39445417/

check out the ongoing work led by @leivaorly.bsky.social! This paper focuses on the impact of high-output HF in pts with MF on survival! pubmed.ncbi.nlm.nih.gov/41814386/

important article looking at the incorporation of molecular data into prognostic scores for secondary myelofibrosis! ashpublications.org/blood/articl...

One of the most grotesque war crimes in modern history And then they bombed the school a second time—killing survivors & rescue workers

Early phase data of selinexor plus ruxolitinib in myelofibrosis - eager to see what the ongoing phase 3 study shows! ashpublications.org/bloodadvance...

proud to be a part of the ongoing collaboration looking at the intersection of MPNs and cardiology led by @leivaorly.bsky.social! Two recent papers out: pubmed.ncbi.nlm.nih.gov/41784313/ pubmed.ncbi.nlm.nih.gov/41779966/

very cool work led by @canersaygin.bsky.social lab looking at the potential for targeting menin in T-cell ALL! aacrjournals.org/mct/article/...

Phase II data on bomedemstat in essential thrombocythemia ashpublications.org/bloodadvance...

an absolute tour-de-force review on the potential role of statins in the management of MPNs! ashpublications.org/bloodadvance...

More data to tease out the impact of TP53 on chronic-phase MPNs! www.nature.com/articles/s41...

great review on everything CALRm directed in MPNs! ashpublications.org/bloodneoplas...

helpful study focused on the development of a prognostic score for CML blast phase! Factors are: -blast percentage, platelet count, age (all at onset of CML-BP), -immunophenotype -extramedullary disease -previous history of CML www.nature.com/articles/s41...

useful real-world study supporting the addition of midostaurin to intensive chemo in adults ≥60 with FLT3m AML pubmed.ncbi.nlm.nih.gov/41671383/

This is straight-up Nazi rhetoric from Musk, and the only tiny thing I can do is address myself to those of you who are still on X. No more excuses about how you need "reach" or how good the conversation is there or the importance of debate. You will not regret walking away, and it's time.

new publication in @ascocancer.bsky.social JCO detailing the PVEK experience in BPDCN! ascopubs.org/doi/full/10....

excellent paper in @bloodjournal.bsky.social on how prior non-response to blinatumomab is associated with poor outcomes in pts with ALL that subsequently received Brexu-cel ashpublications.org/blood/articl...

There is literally no better example of textbook fascistic thinking than "Who cares about human rights when the rich are doing so very well"

Enjoyed this viewpoint on the murky line between high-risk MDS and AML! www.thelancet.com/journals/lan...

very helpful @bloodjournals.hematology.org article on use of ropeginterferon alfa-2b in pregnant patients with MPNs ashpublications.org/bloodadvance...

glad to be a part of this effort led by @michaeldrazer.bsky.social characterizing hematologic complications in patients treated with PARPi -17 of 265 pts treated with PARPi underwent BM Bx for workup of abnormal blood counts -8 of 17 diagnosed with t-MN pubmed.ncbi.nlm.nih.gov/41609051/

It's a good day to call your Senators and tell them that you are watching and that you will not forget what they do, or fail to do.

enjoyed this @bloodjournal.bsky.social article on the next wave of JAK inhibitors in development for MPNs! ashpublications.org/blood/articl...

By who? Who shot the person dead? You saw the video. We all know a federal agent shot a man dead who was prone on the ground. Also, it's not "according to officials." It's according to verified video seen with your eyes. Not saying what anyone can obviously see with their eyes is a form of lying.

check out our work now in the latest issue of BJH! We report on the efficacy of therapies in patients with acute leukemia previously treated with revumenib onlinelibrary.wiley.com/doi/10.1111/...

Phase III study of intensive chemo +/- dasatinib in CBF AML is out in @bloodjournal.bsky.social - no EFS benefit seen in the investigational arm! www.sciencedirect.com/science/arti...

ICE keeps saying the people protesting it are being paid without any evidence, but we have receipts showing that the people *defending* ICE are absolutely being paid. And yet we only hear lies about the former on cable news.

new paper led by Dr Irum Khan looking at clinical and sociodemographic contributors to ICU admission in patients with AML getting intensive chemo! Grateful to be a part of this Chicagoland collaboration haematologica.org/article/view...

check out this paper in @bloodjournals.hematology.org led by @talhabadarmd.bsky.social on PPM1D in CHIP/CCUS! Glad to contribute to this effort pubmed.ncbi.nlm.nih.gov/41499760/

glad to contribute to this effort in @bloodjournals.hematology.org looking at statin use and impact on CV outcomes in patients with MPNs! ashpublications.org/bloodadvance...